Who are Nicotine patch, nicotine inhaler, bupropion's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-patch-nicotine-inhaler-bupropion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nicotine patch, nicotine inhaler, bupropion — Competitive Intelligence Brief

Nicotine patch, nicotine inhaler, bupropion (Nicotine patch, nicotine inhaler, bupropion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Smoking cessation agent combination. Area: Addiction Medicine / Smoking Cessation.

marketed Smoking cessation agent combination Nicotinic acetylcholine receptors (nicotine); dopamine and norepinephrine transporters (bupropion) Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

Nicotine patch, nicotine inhaler, bupropion (Nicotine patch, nicotine inhaler, bupropion) — University of Medicine and Dentistry of New Jersey. This combination therapy uses nicotine replacement (patch and inhaler) plus bupropion to reduce nicotine cravings and withdrawal symptoms while addressing the neurochemical basis of nicotine dependence.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine patch, nicotine inhaler, bupropion TARGET	Nicotine patch, nicotine inhaler, bupropion	University of Medicine and Dentistry of New Jersey	marketed	Smoking cessation agent combination	Nicotinic acetylcholine receptors (nicotine); dopamine and norepinephrine transporters (bupropion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Smoking cessation agent combination class)

University of Medicine and Dentistry of New Jersey · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicotine patch, nicotine inhaler, bupropion — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-patch-nicotine-inhaler-bupropion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab